Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015105 | 0.95 | MAPK14 (0.57) | MAPK14MAPK11LPAR2MAPK8 | |
| SCHEMBL4021362 | 0.90 | MAPK14 (0.51) | MAPK14MAPK11LPAR2MAPK8PTGS2 | |
| SCHEMBL4840801 | 0.89 | MAPK14 (0.59) | MAPK14MAPK11LPAR2MAPK8PTGS2 | |
| SCHEMBL4012451 | 0.89 | MAPK14 (0.58) | MAPK14MAPK11LPAR2MAPK8 | |
| SCHEMBL4844809 | 0.84 | MAPK14 (0.53) | MAPK14MAPK11LPAR2MAPK8PTGS2 | |
| SCHEMBL4013208 | 0.84 | MAPK14 (0.52) | MAPK14MAPK11LPAR2MAPK8PTGS2 | |
| SCHEMBL4020032 | 0.84 | MAPK14 (0.43) | MAPK14MAPK11LPAR2BRD4 | |
| SCHEMBL4016081 | 0.83 | MAPK14 (0.42) | MAPK14MAPK11LPAR2 | |
| SCHEMBL4012931 | 0.82 | MAPK14 (0.43) | MAPK14MAPK11MAPK8BRD4 | |
| SCHEMBL4015197 | 0.82 | MAPK14 (0.46) | MAPK14MAPK11LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608603-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1919914-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| WO-2007023115-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049597-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAPK9, MAPK3 | MAPK14 22/4885MAPK11 24/4885LPAR2 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.